Poxel SA has raised €17.7 million in a private share placement concurrent with the release of new preclinical data for one of its two clinical-stage compounds for non-alcoholic steatohepatitis (NASH). The studies suggested a possible benefit for the compound as a combination therapy, as well an agent for treating other metabolic diseases.
